CALCA and migraine disorder: Recently, monoclonal antibodies that target the CGRP pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine (Wrobel Goldberg and Silberstein, 2015; Israel et al., 2018).